Translating Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,510,085.00
Summary
Breast cancer is the most common cancer in women. Despite improvements in prevention, detection and treatment, it is the 2nd most common cause of cancer death in Australian women. Research advances in the last decade have improved our understanding of the pathways from susceptibility to progression and metastasis but this has mostly not yet translated into better outcomes. This program aims to translate some of our fundamental discoveries to improve outcome for affected women and their families.
Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
Improving Cancer Management By Direct Detection With Diffusion-weighted Magnetic Resonance Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$421,549.00
Summary
Despite reliable methods of prostate and breast cancer diagnosis there remains considerable uncertainty as to whether the detected disease will have a significant impact on a patient’s quality of life. This uncertainty is largely due to the inability of current detection methods to show the extent of disease. This project will address this problem by developing new MRI methods that directly measure the microscopic tissue properties that define cancer.
Role Of Cyclin E2 In Hormone-responsive Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$328,194.00
Summary
The female hormone estrogen stimulates the growth of breast cancers by promoting cell reproduction. We have found that cyclin E2, which is part of the machinery that controls cell reproduction, responds to estrogen. Since abnormally high levels of cyclin E2 are linked with earlier relapse in breast cancer, we wish to understand what role it plays in estrogen action and in breast cancer, how its levels are controlled, and whether too much cyclin E2 interferes with drugs that block estrogen action
Translating Molecular Pathology Into Cancer Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
The aim of this research is focussed on translation of basic science through to the clinic by introducing novel cancer diagnostics and technologies. Other integral aims are to identify new changes in DNA and other cancer cell markers in patients, assess the clinical utility of these as biomarkers (surrogates of cancer behaviour) and to conduct novel clinical trials with newly identified molecular targets of cancer and new therapeutics and combinations to assess their efficacy.
Histopathological, Magnetic Resonance (MR) And Ultrasound Correlates Of Mammographic Density In BRCA1-2 Mutation Carriers
Funder
National Health and Medical Research Council
Funding Amount
$345,931.00
Summary
Mammographic density (MD), is a major risk factor for breast cancer. The nature of breast tissue underlying MD is not clear. The study will clarify the nature of breast tissue underlying MD as well as determining the breast MRI and ultrasound features that correlate with MD. These findings will enhance knowledge of breast cancer development, and should help to avoid mammography to screen young, high risk women and fulfil a priority objective of Cancer Australia
Molecular Determinants Of Susceptibility And Progression In Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$6,006,551.00
Summary
Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic ....Breast cancer is heterogeneous, making management a challenge. High-grade cancers including the ‘basal’ type are aggressive, often found in young women and have a propensity for distant spread. They are also associated with a BRCA1 gene mutation. We will study mechanisms that predispose some women to develop breast cancer, the process that allows cancers to grow at distant sites such as the brain and lungs, and how DNA repair proteins are implicated. This will allow development of new diagnostic tools and treatments.Read moreRead less
Risk Of Recurrence After Diagnosis Of Invasive Breast Cancer By Molecular Subtype As Defined By ER, PR And Her2 Status
Funder
National Health and Medical Research Council
Funding Amount
$500,622.00
Summary
Breast cancer is a heterogeneous disease. Molecular subtypes have been identified that differ in terms of prognosis and response to treatment. This study aims to estimate recurrence free survival of breast cancer by molecular subtypes in a population-based sample of Australian women. The results will assist clinicians to guide their therapeutic decisions and will inform women about their anticipated outcome after diagnosis of breast cancer.
From Transcriptome Metanalysis To Targeted Therapies In Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$483,363.00
Summary
We identified a gene expression signature, a genetic fingerprint, that identifies patients who are affected by very aggressive forms of breast cancer. In this project, we will develop a clinically relevant test that can be used to guide treatment planning against aggressive types of breast cancer to improve survival rates. In addition we will validate new and novel targets for future drug development against these aggressive subtypes.